| Description | BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques. |
| Synonyms | UNII-0Z473OO6GB, BMS212122, BMS 212122 |
| molecular weight | 754.76 |
| Molecular formula | C43H36F6N4O2 |
| CAS | 194213-64-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (66.25 mM) |
| References | 1. Hewing B, et al. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013 Mar;227(1):125-9. 2. Robl JA, et al. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001 Mar 15;44(6):851-6. 3. Peled M, et al. A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS One. 2017;12(3):e0173975. |